Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 6;57(3):791–803. doi: 10.3892/ijo.2020.5094

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Papoutsidakis et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Effect of lumican downregulation and exogenous TGF-β2 on chon-drosarcoma cell growth and Smad2 activation. HTB94 cells were treated for 48 h with specific siRNA against lumican. A non-specific RNA sequence was used as a control (siScr). Following 24 h of transfection with siLum, cells were treated with TGF-β2 (10 ng/ml) in 0% FBS DMEM. (A) Cell number was determined using fluorometric CyQUANT Assay kit (B) Representative blots of Smad2 (60 kDa), p-Smad2 (60 kDa), and actin (42 kDa) are presented. (C) Smad2 and p-Smad2 protein bands were densitometrically analyzed and adjusted against actin, and the ratio of p-Smad2/Smad2 was measured and presented. The position of the nearest respective protein marker band is depicted to the right. Results represent the average of 3 separate experiments. Data are the means ± SEM; ^*P≤0.05, ^**P≤0.01 and ^***P≤0.001, statistically significant difference between siScr and siLum treatments. ^†P≤0.05 and †††P≤0.001, statistically significant difference between control and TGF-β2 treatment groups.